• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Mcleod Ian claimed ownership of 16,042 shares (SEC Form 3)

    4/11/25 4:46:31 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    McLeod Ian

    (Last) (First) (Middle)
    32 WIGGINS AVENUE

    (Street)
    BEDFORD MA 01730

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/05/2025
    3. Issuer Name and Ticker or Trading Symbol
    Anika Therapeutics, Inc. [ ANIK ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    VP, CAO and Treasurer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 16,042 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Restricted Stock Unit (1) (1) Common Stock 2,197 $0 D
    Stock Option (Right to Buy) (2) 03/09/2033 Common Stock 2,362 $29.6(3) D
    Restricted Stock Unit (4) (4) Common Stock 5,317 $0 D
    Stock Option (Right to Buy) (5) 03/15/2034 Common Stock 6,346 $27.98(3) D
    Restricted Stock Unit (6) (6) Common Stock 11,324 $0 D
    Restricted Stock Unit (7) (7) Common Stock 2,536 $0 D
    Explanation of Responses:
    1. Each RSU represents the contingent right to receive one share of the Company's common stock. 6,590 RSUs were granted on March 9, 2023 and the RSUs vest in three equal annual installments beginning March 9, 2024.
    2. 7,086 stock options were granted on March 9, 2023. The stock options vest in three equal annual installments beginning on March 9, 2024.
    3. Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
    4. 7,976 RSUs were granted on March 15, 2024. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 15, 2025.
    5. 9,519 stock options were granted on March 15, 2024. The stock options vest in three equal annual installments beginning on March 15, 2025.
    6. 11,324 RSUs were granted on March 14, 2025. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on each vest date. The RSUs vest in three equal annual installments beginning March 14, 2026.
    7. 2,536 RSUs were granted on March 14, 2025. Each RSU represents the contingent right to receive, at the Company's discretion, one share of the Company's common stock, or the cash equivalent of the closing price of one share of the Company's common stock, on the vest date. The 2,536 RSUs represent the Target number of shares that may be earned in conjunction with certain market metrics prescribed under the terms of the performance-based phantom RSU award. The award shall cliff vest on the 3rd anniversary of the grant date, subject to the Compensation Committee's determination of achievement of the award prior to the vest date. The number of shares earned and subject to vest, as determined by the Compensation Committee, may be in a range from Threshold (50% of Target) to Maximum (200% of Target). No shares shall vest for achievement under Threshold.
    /s/ Ian McLeod 04/11/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANIK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation

      6/5/25 5:00:54 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options ("Options") covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market ("Closing Price") on the grant date, to two newly hired non-executive employees. The grants were made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, were approved by the comp

      5/12/25 5:00:24 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Reports First Quarter 2025 Financial Results

      First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 ResultsAnika announced first quarter reven

      5/9/25 7:05:26 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

      B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Barrington Research reiterated coverage on Anika Therapeutics with a new price target

      Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

      11/1/24 10:25:08 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics upgraded by Barrington Research with a new price target

      Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

      8/14/23 9:16:10 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, CFO & COO Griffin Stephen D. converted options into 12,840 shares and covered exercise/tax liability with 3,769 shares, increasing direct ownership by 1,134% to 9,871 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      6/5/25 5:01:13 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • New insider Mcleod Ian claimed ownership of 16,042 shares (SEC Form 3)

      3 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      4/11/25 4:46:31 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SVP, Chief Operations Officer Nunes Anne covered exercise/tax liability with 1,068 shares and converted options into 3,637 shares, increasing direct ownership by 14% to 20,654 units (SEC Form 4)

      4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

      3/18/25 5:16:55 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care

    $ANIK
    SEC Filings

    See more
    • SEC Form 10-Q filed by Anika Therapeutics Inc.

      10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

      5/9/25 2:30:08 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • Anika Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Anika Therapeutics, Inc. (0000898437) (Filer)

      5/9/25 7:20:20 AM ET
      $ANIK
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Anika Therapeutics Inc.

      DEFA14A - Anika Therapeutics, Inc. (0000898437) (Filer)

      4/28/25 5:26:37 PM ET
      $ANIK
      Medical/Dental Instruments
      Health Care